Sanjiv Patel - Jun 30, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: President and CEO, Director
Signature: /s/ Brian Adams, as attorney-in-fact
Stock symbol: RLAY
Transactions as of: Jun 30, 2022
Transactions value $: $11,591
Form type: 4
Date filed: 7/8/2022, 04:22 PM
Previous filing: May 27, 2022
Next filing: Sep 15, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Award	$11.6K	+814	+0.32%	$14.24	255K	Jun 30, 2022	Direct	F1, F2
holding	RLAY	Common Stock						675K	Jun 30, 2022	By The Patel Family Irrevocable Trust of 2019	F3
holding	RLAY	Common Stock						433K	Jun 30, 2022	By The SSP Irrevocable Trust of 2020	F3

Showing 1 to 3 of 3 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2	In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2022.
F3	These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.